**Highlights of This Issue 1019**

**REVIEW**

1021  **Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors**
Rodrigo Dienstmann, Jordi Rodon, Violeta Serra, and Josep Tabernero

**SMALL MOLECULE THERAPEUTICS**

1032  **Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer**
Niranjan Awasthi, Changhua Zhang, Anna M. Schwarz, Stefan Hinz, Margaret A. Schwarz, and Roderich E. Schwarz

1044  **The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells**
Elgilda Musi, Grazia Ambrosini, Elisa de Stanchina, and Gary K. Schwartz

1054  **Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na**

1067  **Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth**
Qiang Wu, Manish Kohli, H. Robert. Bergen III, John C. Cheville, R. Jeffrey Karmes, Hong Cao, Charles Y.F. Young, Donald J. Tindall, Mark A. McNiven, and Krishna Vanaja Donkena

1078  **Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway**

1092  **UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency**
Maria Vincenza Carriero, Katia Bifulco, Michele Minopoli, Liliana Lista, Ornella Maglio, Luigi Mele, Gioconda Di Carluccio, Mario De Rosa, and Vincenzo Pavone

1105  **Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models**
Xiaoping Zhang, Hua Lv, Qingyu Zhou, Rana Elkholy, Jerry E. Chipuk, M.V. Ramana Reddy, E. Premkumar Reddy, and James M. Gallo

1117  **Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 of Development of the Patient Stratification Strategy for Clinical Trials**

1130  **Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer**
Ning Wei, Edward Chu, Peter Wipf, and John C. Schmitz
ABOUT THE COVER

Angiogenesis is important for tumor progression. In squamous cell carcinoma of the head and neck (SCCHN), angiogenesis is activated by cytokines including IL-6 and VEGF. Galanin receptor 2 (GALR2) is a G protein-coupled receptor that induces aggressive growth in SCCHN. GALR2 stimulates tumor angiogenesis in SCCHN via p38-mediated inhibition of tristetraprolin (TTP) with resultant enhanced cytokine secretion. Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN. For details, see article by Banerjee, Van Tubergen, and colleagues on page 1323.